Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 12/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13854455 | 1.00 | CYP4F2 (0.37) | CYP4F2CYP4A11OPRM1SLC6A2SLC6A4 | |
| Cadaverine Tartrate SCHEMBL4218350 | 0.89 | OPRM1 (0.32) | CYP4F2CYP4A11OPRM1SLC6A2SLC6A4 | |
| SCHEMBL29896716 | 0.84 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL14804610 | 0.84 | OPRM1 (0.38) | CYP4F2CYP4A11OPRM1SLC6A2SLC6A4 | |
| SCHEMBL8516845 | 0.84 | OPRM1 (0.38) | CYP4F2CYP4A11OPRM1SLC6A2SLC6A4 | |
| SCHEMBL15367602 | 0.81 | CYP2D6 (0.42) | CYP4F2CYP4A11OPRM1SLC6A2SLC6A4 | |
| SCHEMBL28383552 | 0.80 | CYP2D6 (0.34) | CYP4F2CYP4A11SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2470075 | 0.79 | OPRM1 (0.35) | CYP4F2CYP4A11OPRM1SLC6A2SLC6A4 | |
| SCHEMBL17031937 | 0.78 | CYP4F2 (0.48) | CYP4F2CYP4A11CYP2D6NPSR1 | |
| SCHEMBL13092542 | 0.78 | CYP4F2 (0.34) | CYP4F2CYP4A11OPRM1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283530-A1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND APPLICATION THEREOF | BEIJING LIHE TECH LTD (CN) | 2017-10-05 | — | — | US | claimed |
| US-20160272733-A1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND APPLICATION THEREOF | BEIJING LIHE TECHNOLOGY LTD. (CN) | 2016-09-22 | — | — | US | claimed |
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238633-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20190169328-A1 | OLEFIN POLYMERIZATION CATALYST CARRIER, SOLID CATALYST COMPONENT AND USE THEREOF | RENQIU LIHE TECH LTD (CN) | 2019-06-06 | — | — | US | disclosed |
| US-10208146-B2 | Catalyst component for olefin polymerization and application thereof | BEIJING LIHE TECHNOLOGY LTD. (CN) | 2019-02-19 | — | — | US | disclosed |
| US-20170355792-A1 | OLEFIN POLYMERIZATION CATALYST CARRIER, SOLID CATALYST COMPONENT AND USE THEREOF | RENQIU LIHE TECH LTD (CN) | 2017-12-14 | — | — | US | disclosed |
| US-20170283530-A1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND APPLICATION THEREOF | BEIJING LIHE TECH LTD (CN) | 2017-10-05 | — | — | US | disclosed |
| US-20160272733-A1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND APPLICATION THEREOF | BEIJING LIHE TECHNOLOGY LTD. (CN) | 2016-09-22 | — | — | US | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007097937-A1 | PYRROLIDINE DERIVATIVES AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | CYP4F2 2249/4885CYP4A11 2627/4885OPRM1 2391/4885 |
| US-10208146-B2 | Catalyst component for olefin polymerization and application thereof | TEC, ETFA, TECR | CYP4F2 31/4885CYP4A11 171/4885OPRM1 303/4885 |
| US-20190169328-A1 | OLEFIN POLYMERIZATION CATALYST CARRIER, SOLID CATALYST COMPONENT AND USE THEREOF | COG2, GTF2I, POF1B | CYP4F2 148/4885CYP4A11 660/4885OPRM1 13/4885 |
| US-20070232610-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | CYP4F2 2249/4885CYP4A11 2627/4885OPRM1 2391/4885 |
| US-20170283530-A1 | CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND APPLICATION THEREOF | TEC, ETFA, TECR | CYP4F2 31/4885CYP4A11 171/4885OPRM1 303/4885 |
| US-20170355792-A1 | OLEFIN POLYMERIZATION CATALYST CARRIER, SOLID CATALYST COMPONENT AND USE THEREOF | COG2, COG7, COG4 | CYP4F2 251/4885CYP4A11 1061/4885OPRM1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.